Wall Street brokerages expect Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to post sales of $10.10 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Adamas Pharmaceuticals’ earnings. The lowest sales estimate is $9.30 million and the highest is $11.00 million. The firm is expected to announce its next quarterly earnings results on Thursday, November 1st.

On average, analysts expect that Adamas Pharmaceuticals will report full year sales of $33.23 million for the current financial year, with estimates ranging from $31.23 million to $36.12 million. For the next fiscal year, analysts forecast that the company will post sales of $95.31 million, with estimates ranging from $75.00 million to $116.70 million. Zacks’ sales averages are an average based on a survey of analysts that follow Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.15. Adamas Pharmaceuticals had a negative return on equity of 104.86% and a negative net margin of 1,138.59%. The business had revenue of $7.57 million for the quarter, compared to analyst estimates of $4.84 million.

ADMS has been the topic of a number of analyst reports. HC Wainwright set a $45.00 target price on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 6th. BidaskClub lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 18th. ValuEngine lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 28th. Finally, Mizuho reiterated a “buy” rating and issued a $75.00 price target on shares of Adamas Pharmaceuticals in a research note on Friday, August 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company’s stock. Adamas Pharmaceuticals currently has an average rating of “Buy” and an average target price of $46.33.

Shares of NASDAQ ADMS traded up $0.80 during midday trading on Friday, reaching $19.93. 405,405 shares of the company’s stock were exchanged, compared to its average volume of 755,763. Adamas Pharmaceuticals has a 52-week low of $17.68 and a 52-week high of $44.00. The firm has a market cap of $521.24 million, a price-to-earnings ratio of -4.94 and a beta of 1.38. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.74 and a current ratio of 9.92.

In related news, CFO Alfred G. Merriweather sold 1,665 shares of the business’s stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $19.18, for a total transaction of $31,934.70. Following the sale, the chief financial officer now owns 25,460 shares of the company’s stock, valued at $488,322.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 24.60% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp increased its holdings in shares of Adamas Pharmaceuticals by 23.1% in the second quarter. Northern Trust Corp now owns 274,563 shares of the specialty pharmaceutical company’s stock valued at $7,092,000 after buying an additional 51,508 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Adamas Pharmaceuticals by 12.7% in the second quarter. Bank of New York Mellon Corp now owns 246,352 shares of the specialty pharmaceutical company’s stock valued at $6,363,000 after buying an additional 27,696 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Adamas Pharmaceuticals by 318.2% in the second quarter. Millennium Management LLC now owns 342,180 shares of the specialty pharmaceutical company’s stock valued at $8,839,000 after buying an additional 260,360 shares in the last quarter. SCP Investment LP increased its holdings in shares of Adamas Pharmaceuticals by 4.9% in the second quarter. SCP Investment LP now owns 210,191 shares of the specialty pharmaceutical company’s stock valued at $5,429,000 after buying an additional 9,732 shares in the last quarter. Finally, MetLife Investment Advisors LLC increased its holdings in shares of Adamas Pharmaceuticals by 53.0% in the second quarter. MetLife Investment Advisors LLC now owns 10,769 shares of the specialty pharmaceutical company’s stock valued at $278,000 after buying an additional 3,729 shares in the last quarter. 95.13% of the stock is currently owned by institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Further Reading: Dividend

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.